Oncolytics Biotech Inc. provided an update on its intellectual property portfolio and efforts to extend patent protection for pelareorep.
The company filed a Track 1 manufacturing patent application with the USPTO to potentially extend patent coverage beyond 2044.
Oncolytics plans to file additional patent applications relating to the manufacture and method-of-use covering novel therapeutic uses of pelareorep.
Track 1 Prioritized Examination Patent Application
Filed with USPTO to focus on manufacturing-related innovations for pelareorep with potential term extension to 2044.
Planned Additional Patent Filings
Additional patent applications in progress to provide potential IP protection beyond 2044.
Long-Term Value Creation Strategy
Intellectual property extension is a core pillar to protect innovation and increase long-term value for shareholders.
- Oncolytics expects a final action in Q3 2026 regarding the manufacturing patent application.
- Continued pursuit of IP opportunities in 2026 to support late-stage development and future commercialization of pelareorep.
The efforts to extend intellectual property protection for pelareorep demonstrate Oncolytics' commitment to innovation and long-term value creation.